Ignite Creation Date:
2024-05-06 @ 2:18 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04278222
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2020-02-19
Brief Title:
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 APICAL-GC
Sponsor:
Shanghai Changzheng Hospital
Organization:
Shanghai Changzheng Hospital
Study Overview
Official Title:
Efficacy and Safety of Anlotinib Plus Toripalimab as First-line Regimen in Frail Patients ECOG 2 With Advanced Gastric Cancer APICAL-GC an Open-label Single Arm Phase II Trial
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
Recruiting
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen
Detailed Description:
Anlotinib is a new orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor VEGFR fibroblast growth factor receptor FGFR platelet-derived growth factor receptors PDGFR and c-kit Toripalimab is a humanized immunoglobulin Ig G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 programmed death-1 PD-1 with potential immune checkpoint inhibitory and antineoplastic activities In the present study we design a single-arm single center Phase II trial to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None